




CANONIC

Bringing precision
to medical cannabis

Safe harbor

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Agenda

Introduction

Market &
Challenges

Products &
Go-To-Market

Technology &
Partnerships

Summary

Annexes


1. Evogene group

Our Mission

Commercialize precise & stable medical cannabis products for better therapeutic effects

Mission execution

Canonic aims to quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing elements of the value chain.



Variety development through advanced breeding, seed production and seedling production, will be conducted in-house, while cultivation, formulation and distribution will be conducted through partnerships.

Canonic's team

Management



Dr. Arnon Heyman
CEO

Former VP and GM Ag seeds division
Evogene, CTO BondX technologies



Ofer Haviv
Chairman of the board

Evogene CEO and President



Dr. Inbal Dangoor
Head of R&D

Former Biotech Trait Manager,
Ag seeds division Evogene



Dorit Kreiner
CFO

Former Chief Financial Officer in
Therapix (TASE: THXBY) and NRGene

Advisory board



Dr. Yossi Tam
Cannabinoid clinical research

Director, Multidisciplinary Center for
Cannabinoid Research of the Hebrew
university



Dr. Yariv Brotman
Plant metabolic pathways

Ben Gurion University & Max Planck
institute of Molecular Plant Physiology



Dr. Moshe Bar
Plant breeding

Former Global Head of Scouting and
Strategic Projects at Syngenta and VP
R&D at Zeraim Gedera

Agenda

Introduction

**Market &
Challenges**

Products &
Go-To-Market

Technology &
Partnerships


Summary

Annexes


1. Evogene group

Market

Legal market estimated at ~\$104B in 2024




Medical market estimated at ~\$63B in 2024



Source : Cannabis global report , prohibition partners Nov 2019, numbers in graph are rounded




The opportunity and gap

Addressing phenomenal market growth (14% in US only) will require to overcome significant market challenges



Source: New frontier data (US only)

Key Market challenges



SPECIFICITY

Specific medical indications require tailored active compound profiles. To date, breeding mainly pushed THC levels

YIELD

Legalization is driving steep declines in market prices, giving advantage to high yield products

STABILITY


Substantial variations within varieties produce inconsistent products and therefore inconsistent results

Canonic tackles the market challenges...


Our solution

Based on established world-class genomic expertise and technology we create specific genomic profiles to address market challenges – specificity, yield and stability.

Current cannabis genetic mapping



Canonic: seeing the bigger picture



Cannabis – an optimal crop for our solution

Fact 1

Cannabis has been caught in a time capsule with no access to innovation and technologies

Small intervention - huge impact

Fact 2

Cannabis can be grown for at least 3 growth cycles in a year

Triple development speed

Fact 3

Cannabis is grown in a controlled environment

Consistent performance

Canonics technology platform enable fast & efficient, non-GMO product development

Agenda

Introduction

Market &
Challenges

**Products &
Go-To-Market**

Technology &
Partnerships

Summary

Annexes

1. Evogene group

Product types

Precise⁺

Stable enhancement of
specific active compounds



Category 1:
Medical indication focus
[e.g. Pain/inflammation]



Category 2:
Compound profile focus
[e.g. CBG/CBC]

MetaYield⁺

Stable enhancement of
total plant compounds



Category 3:
Increased compounds/plant
[e.g. Increased trichomes prevalence]



Category 4:
Increased compounds/area
[e.g. Dwarf - early flowering]

Precise⁺ Products

Category 1: Medical indication focus




We use proprietary pre-clinical trials to guide our breeding program to specific medical indications

✓ **Market value - \$16B***

Medical cannabis is anticipated to reach 10% of the \$160B Chronic Pain and Inflammation market

*Based on 10% of the current pain management and inflammation market (Visual Capitalist data).

Category 2: Compound profile focus



We identify specific minor cannabinoids and optimize their biosynthesis *in planta*

✓ **Market value- \$15B****

CBG is priced at 200\$ per gr.
At 5% CBG the revenue per acre is 17.5M\$

**Estimating those cannabinoids will reach 60% of the comparable CBD market in 2025 (A.G.P. Market survey).

Agreement for Pre-Clinical Studies



Canonix Announces an Agreement with Hadassah Medical Center for Pre-Clinical Studies to Support the Development of Canonix's Medical Cannabis Products

The studies will focus on inflammatory indications at Prof. Reuven Or's laboratory

Rehovot, Israel – January 27, 2020 – Canonix, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical Cannabis products, announces today an agreement with Hadasit, Hadassah Medical Center Technology Transfer Company, for pre-clinical studies to support the development of anti-inflammatory medical Cannabis products as part of its *Precise* product program. The work will be conducted by the laboratory of Prof. Reuven Or in Hadassah Medical Center (Ein Kerem, Israel), screening Canonix's Cannabis core collection in inflammatory in-vitro models. These studies are expected to support the development of Canonix's unique Cannabis varieties with anti-inflammatory properties.

MetaYield+ Products

Category 3: Increased compounds/plant



WILD TYPE



MODIFIED TYPE



Active compounds concentration is effected by the trichome population, we have proprietary IP for **trichome enhancement**

✓ **Market Value- \$5B***

10% increase in trichome prevalence can increase revenue per acre by >\$1.9M

*Based on 10% yield increase at 2500-acre estimation and market forecast by Prohibition Partners.

Category 4: Increased compounds/area



WILD TYPE



MODIFIED TYPE



Yield per area is affected by plant architecture, we have proprietary knowhow for plant morphology and dwarfing

✓ **Market value - \$3.5B***

10% annual yield increase (add. 2 cycles/y) can increase annual revenue per acre by >1.3M\$

Initiation of Cultivation & Breeding Program




Canonix Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel – November 6, 2019 – Canonix, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

Go-to-Market



Agenda

Introduction

Market &
Challenges

Products &
Go-To-Market


**Technology &
Partnerships**

Summary

Annexes


1. Evogene group

What do we need to lift the curtain?



Enabling technology start to end

Canonic holds exclusive access to assets along the entire innovation value chain for improved varieties development



Innovation will transform the cultivation, processing, sale, and consumption of cannabis in legal markets (New Frontier data 2019)

Harnessing IP and Data



An immense IP portfolio


Within the top 10 companies in the world holding plant genetics know how & IP



High quality data



Multilayer Hubs



Trichomes

Growth rate and phenology

Plant architecture

Abiotic stress tolerance

Disease resistance

> 200 plant species

> Dozens of Cannabis lines

> 3×10^9 data points

> 1000 experiments

> 10 Omic data types

Genome


Transcriptome

Metabolome

Phenotypes

Clinical data*

Applying cutting-edge computational power



Developing in Israel's top cannabis R&D facilities



22,000 sqf of greenhouses (including quarantine greenhouse) integrating the latest technologies for climate control, daylight control, fertilization and irrigation dedicated for cannabis plant development.



Molecular labs and tissue culture facilities fully equipped for cannabis R&D

Regulation

Good Security Practice (GSP) approval and possession license for cannabis from the Israeli Medical Cannabis Agency (IMCA)

Partners and collaborators

Data & Computational



Clinical validation



Agenda

Introduction

Market &
Challenges

Products &
Go-To-Market

Technology &
Partnerships

Summary

Annexes

1. Evogene group

Milestones roadmap



2019

- Establishment of R&D growing facility ✓
- Build cannabis core collection ✓
- Establish initial cannabis database ✓
- Complete at least two cannabis growth cycle ✓
- Establish agronomic protocols ✓



2020

- First trait demonstrated
- Complete three cannabis growth cycles
- Complete establishment of proprietary cannabis database & computational infrastructure
- Expand core collection of cannabis varieties



2021

- Finalize development of first improved variety
- Pre-commercial stage
- Develop extraction & formulation process
- Analyzed clinical effect based on dedicated research

Summary

Canonic develop and bring to market medical grade Cannabis through a revolutionary genomic approach


The market is growing fast, and the **key challenges** are – specificity, yield and stability

Using computational power (Artificial Intelligence, Big Data) we decode the Cannabis genome & identify the specific genomic profiles to overcome market challenges

We have exclusive access to **Evogene's CPB technology platform, IP and infrastructure** for the development of medical cannabis products

Go-To-Market strategy – Variety development through advanced breeding, seed production and seedling production, will be conducted in-house, while cultivation, formulation and distribution will be conducted through partnerships

Two product lines: (I) Stable enhancement of specific active compounds (II) Stable enhancement of total plant compounds



CANONIC

Thank you

— Annex I: Evogene Group —

Evogene parent company-

a world leading computational biology company



MISSION

Evogene (NASDAQ, TASE: EVGN) is a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications



TECHNOLOGY – THE CPB PLATFORM



Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at **'Stage Zero'**.



CPB CAPABILITIES FOR PREDICTION OF INNOVATION

- **Genetic elements** – controlling desired biological processes
- **Small molecules** – active ingredients for chemical based products
- **Microbes** – active ingredients for microbial based products



TARGET MARKETS AND CURRENT ACTIVITIES

- **Agriculture** – Ag-Chemicals, Seed Traits, Ag-Biologicals
- **Human Health** – Human Microbiome, Drug Discovery, Medical Cannabis
- **Industrial Applications** – Castor oil

Evogene – corporate structure

